These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 10671882)
1. Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence. De La Taille A; Benson MC; Bagiella E; Burchardt M; Shabsigh A; Olsson CA; Katz AE BJU Int; 2000 Feb; 85(3):281-6. PubMed ID: 10671882 [TBL] [Abstract][Full Text] [Related]
2. Salvage cryotherapy for recurrent prostate cancer after radiation therapy: the Columbia experience. de la Taille A; Hayek O; Benson MC; Bagiella E; Olsson CA; Fatal M; Katz AE Urology; 2000 Jan; 55(1):79-84. PubMed ID: 10654899 [TBL] [Abstract][Full Text] [Related]
3. Predictors of prostate-specific antigen biochemical recurrence in patients undergoing primary whole-gland prostate cryoablation. Liu YY; Chiang PH; Chuang YC; Lee WC; Cheng YT; Wang HJ Ann Surg Oncol; 2015 May; 22(5):1612-7. PubMed ID: 25287436 [TBL] [Abstract][Full Text] [Related]
4. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life. Hubosky SG; Fabrizio MD; Schellhammer PF; Barone BB; Tepera CM; Given RW J Endourol; 2007 Dec; 21(12):1521-31. PubMed ID: 18186694 [TBL] [Abstract][Full Text] [Related]
5. Five-Year Biochemical Progression-Free Survival Following Salvage Whole-Gland Prostate Cryoablation: Defining Success with Nadir Prostate-Specific Antigen. Kovac E; ElShafei A; Tay KJ; Mendez M; Polascik TJ; Jones JS J Endourol; 2016 Jun; 30(6):624-31. PubMed ID: 26915721 [TBL] [Abstract][Full Text] [Related]
6. Salvage cryotherapy with third-generation technology for locally recurrent prostate cancer after radiation therapy. Lian H; Yang R; Lin T; Wang W; Zhang G; Guo H Int Urol Nephrol; 2016 Sep; 48(9):1461-6. PubMed ID: 27300004 [TBL] [Abstract][Full Text] [Related]
7. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Kupelian PA; Katcher J; Levin HS; Klein EA Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811 [TBL] [Abstract][Full Text] [Related]
8. Salvage Cryoablation for Radiorecurrent Prostate Cancer: Initial Experience at a Regional Health Care System. Safavy S; Jabaji RB; Lu SM; Slezak JM; Cosmatos HA; Williams SG; Finley DS Perm J; 2019; 23():. PubMed ID: 31050644 [TBL] [Abstract][Full Text] [Related]
9. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer. Sakai I; Harada K; Kurahashi T; Muramaki M; Yamanaka K; Hara I; Inoue TA; Miyake H Urol Int; 2006; 76(3):227-31. PubMed ID: 16601384 [TBL] [Abstract][Full Text] [Related]
10. Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-year follow-up. Bahn DK; Lee F; Silverman P; Bahn E; Badalament R; Kumar A; Greski J; Rewcastle JC Clin Prostate Cancer; 2003 Sep; 2(2):111-4. PubMed ID: 15040872 [TBL] [Abstract][Full Text] [Related]
12. Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience. Ghafar MA; Johnson CW; De La Taille A; Benson MC; Bagiella E; Fatal M; Olsson CA; Katz AE J Urol; 2001 Oct; 166(4):1333-7; discussion 1337-8. PubMed ID: 11547068 [TBL] [Abstract][Full Text] [Related]
13. Prostate Specific Antigen Nadir of 0.1 or Less Is a Predictor of Treatment Success in Men Undergoing Salvage Whole Prostate Gland Cryoablation. Nyame YA; Elshafei A; Greene DJ; Arora HC; Given RW; Tay KJ; Polascik TJ; Ross AE; Mouraviev VB; Lugnani F; Jones JS J Endourol; 2017 May; 31(5):497-501. PubMed ID: 28437170 [TBL] [Abstract][Full Text] [Related]
15. Primary Whole-gland Cryoablation for Prostate Cancer: Biochemical Failure and Clinical Recurrence at 5.6 Years of Follow-up. Oishi M; Gill IS; Ashrafi AN; Lin-Brande M; Nassiri N; Shin T; Bove A; Cacciamani GE; Ukimura O; Bahn DK; Abreu ALC Eur Urol; 2019 Feb; 75(2):208-214. PubMed ID: 30274702 [TBL] [Abstract][Full Text] [Related]
16. Salvage radiotherapy for prostate cancer recurrence after cryosurgical ablation. Burton S; Brown DM; Colonias A; Cohen J; Miller R; Rooker G; Benoit R; Merlotti L; Quinn A; Kalnicki S Urology; 2000 Nov; 56(5):833-8. PubMed ID: 11068312 [TBL] [Abstract][Full Text] [Related]
17. The efficacy and complications of salvage cryotherapy of the prostate. Pisters LL; von Eschenbach AC; Scott SM; Swanson DA; Dinney CP; Pettaway CA; Babaian RJ J Urol; 1997 Mar; 157(3):921-5. PubMed ID: 9072600 [TBL] [Abstract][Full Text] [Related]
18. Salvage cryosurgery of the prostate for failure after primary radiotherapy or cryosurgery: long-term clinical, functional, and oncologic outcomes in a large cohort at a tertiary referral centre. Wenske S; Quarrier S; Katz AE Eur Urol; 2013 Jul; 64(1):1-7. PubMed ID: 22840351 [TBL] [Abstract][Full Text] [Related]
19. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer? Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328 [TBL] [Abstract][Full Text] [Related]
20. Salvage cryoablation for local recurrence of prostatic cancer after curative therapy. Barat M; Colleter L; Mongiat-Artus P; Jolibois Z; Quero L; Hennequin C; Desgrandchamps F; de Kerviler E Diagn Interv Imaging; 2019 Nov; 100(11):679-687. PubMed ID: 31331832 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]